ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Famotidine

Also written as “Atazanavir+Ritonavir+Tenofovir+Famotidine”, “Famotidine Tablets, 40 mg” and “Atazanavir/Ritonavir + Famotidine”.

Its studies are mostly in COVID-19 · HIV Infections · Ulcer · Arthritis, Juvenile · Heartburn, led by 8 companies.

Drug pageFamotidine: every studyMany companies study it; this page follows only the 13 they lead. All 52 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 202113 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Leidos Life Sciencesits history only30 open or runningphase 2since Oct 7, 2021Oct 7, 2021none ahead
Amgenits history only20 open or runningphase 4since Mar 20, 2012Mar 19, 2007none ahead
Perrigoits history only20 open or runningphase 1since Dec 3, 2008Dec 3, 2008none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Feb 18, 2010Feb 18, 2010none ahead
Astellas Pharmaits history only10 open or runningphase 3since Sep 1, 2005Sep 1, 2005none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Jan 12, 2012Jan 12, 2012none ahead
drpykessupplements.comits history only10 open or runningphase 4since Sep 21, 2020Sep 21, 2020none ahead
Pfizerits history only10 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2005First study: phase 3 study in Gastroesophageal RefluxNew to Astellas PharmaAstellas Pharma · NCT00141960 · 480 enrolled · Japan
  2. Mar 19, 2007Amgen’s first study: phase 3 study in UlcerNew to AmgenAmgen · NCT00450216 · 906 enrolled
  3. Dec 3, 2008Perrigo’s first studies: 2 phase 1 studies in BioavailabilityNew to PerrigoPerrigo · NCT00803192, NCT00802828
  4. Feb 18, 2010Sun Pharmaceutical Industries’ first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01079065, NCT01079052
  5. Jan 12, 2012Dr. Reddy's Laboratories’ first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511731 · 30 enrolled · Canada
  6. Mar 20, 2012Phase 4 study in Arthritis, JuvenileAmgen · NCT01563185 · 12 enrolled · United States
  7. Mar 24, 2014Pfizer’s first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
  8. Sep 21, 2020drpykessupplements.com’s first study: phase 4 study in COVID-19New to drpykessupplements.comdrpykessupplements.com · NCT04565392 · United States
  9. Oct 7, 2021Leidos Life Sciences’ first studies: 3 phase 2 studies in COVID-19New to Leidos Life SciencesLeidos Life Sciences · NCT05085574, NCT05077969, NCT05077332

TargetBeta

HRH2 →read by rule
“Histamine H2 receptor antagonist”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05085574COVID-192WithdrawnLeidos Life SciencesFeb 7, 20230
NCT05077969COVID-19 · United States2TerminatedLeidos Life SciencesJun 28, 20224
NCT05077332COVID-19 · United States2CompletedLeidos Life SciencesNov 10, 20254
NCT04565392COVID-19 · United States4Withdrawndrpykessupplements.comNov 1, 20210
NCT02097329Healthy · United States1CompletedPfizerJun 201427
NCT01563185Arthritis, Juvenile · United States4CompletedAmgenMar 201512
NCT01511731Healthy · Canada1CompletedDr. Reddy's LaboratoriesOct 199830
NCT01079065Healthy · India–CompletedSun Pharmaceutical IndustriesNov 200732
NCT01079052Healthy · India–CompletedSun Pharmaceutical IndustriesNov 200724
NCT00803192Bioavailability1CompletedPerrigoJun 200444
NCT00802828Bioavailability1CompletedPerrigoJun 200444
NCT00450216Ulcer3CompletedAmgenAug 2008906
NCT00141960Gastroesophageal Reflux · Japan3CompletedAstellas Pharma480

How it is read

Names in the registry

  • “Famotidine”, 8 entries
  • “Atazanavir+Ritonavir+Tenofovir+Famotidine”, 4 entries
  • “Famotidine Tablets, 40 mg”, 2 entries
  • “Atazanavir/Ritonavir + Famotidine”, 2 entries
  • “Nirogacestat and Famotidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.